DOCSLIB.ORG

Non Conventional Synthetic Strategies of Stapled Peptides: Modulation of Secondary Structures to Optimise Biological Recognition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non Conventional Synthetic Strategies of Stapled Peptides: Modulation of Secondary Structures to Optimise Biological Recognition PhD THESIS OF THE UNIVERSITY OF CERGY-PONTOISE CO-TUTORED WITH THE UNIVERSITY OF FLORENCE Non conventional synthetic strategies of stapled peptides: modulation of secondary structures to optimise biological recognition presented by : Chiara TESTA PhD discussed on March 26th 2012, Composition of the evaluation committee: Pr. Solange LAVIELLE Rapporteur Pr. Luis MORODER Rapporteur Pr. Anna Maria PAPINI Directrice de thèse Pr. Nadège GERMAIN Directrice de thèse Pr. Paolo ROVERO Directeur de thèse Pr. Michael CHOREV Examinateur Pr. Jacques AUGE Examinateur Pr Andrea GOTI Examinateur Chiara Testa, PhD Thesis Table of contents INTRODUCTION .................................................................................................................. 1 1 Difficult peptide synthesis optimized by microwave-assisted approach: a case study of PTHrP(1–34)NH2 ......................................................................................... 18 1.1 The Parathyroid hormone (PTH) and the Parathyroid hormone-related protein (PTHrP) .................................................................................... 18 1.2 Microwave assisted peptide synthesis .................................................. 20 1.2.1 Thermal effects ..................................................................................... 21 1.2.2 Specific non-thermal effects ................................................................. 22 1.2.3 Modes .................................................................................................... 22 1.3 Synthetic strategies for difficult peptide sequences .............................. 23 1.4 Synthesis of PTHrP(1-34) ..................................................................... 25 1.5 MW-assisted mini-cleavage of PTHrP(1-34)NH2 fragments ............... 26 1.5.1 MW-assisted mini-cleavage protocol of 19-34 fragment of ................. 27 PTHrP(1-34)NH2: a case study of multi-arginine containing peptides. 27 1.5.2 Charachterization of PTHrP(1-34)NH2 fragments by UPLC-ESI-MS analysis .................................................................................................. 29 1.5.3 Characterization of the 12-34 fragment of PTHrP(1-34)NH2 by UPLS- ESI-MS/MS analysis ............................................................................. 32 1.6 RP-HPLC Semi-preparative of PTHrP(1–34)NH2 ............................... 33 1.7 Results ................................................................................................... 33 1.8 Advantages of MW irradiation in SPPS ............................................... 34 2 Intramolecular i-to-(i+5) Side-Chain-to-Side Chain Cyclization to stabilize β-turn Secondary Structures: the melanocortin peptides hormones ................................. 38 2.1 The Endocrine System .......................................................................... 38 2.1.1 Peptide hormones .................................................................................. 41 2.1.2 The Nervous and Endocrine Systems ................................................... 43 2.2 Melanocortin peptide hormones ........................................................... 44 2.2.1 G Protein-coupled Melanocortin receptors: MCRs .............................. 47 2.2.2 Development of Agonist for MCRs ...................................................... 51 2.3 Stabilization of β-turn conformation in melanocortin like peptide by Click Chemistry .................................................................................... 54 i Chiara Testa, PhD Thesis 2.4 Click Chemistry .................................................................................... 56 2.5 Synthetic Strategy ................................................................................. 60 2.6 Synthesis of non-coded amino acids ..................................................... 61 2.6.1 Synthesis of Nα-Fmoc-ω-azido-α-amino acids ..................................... 61 2.6.2 Synthesis of Nα-Fmoc-ω-alkynyl-α-amino acids .................................. 63 2.6.3 Collection of linear peptide precursor .................................................. 65 2.6.4 Collection of triazole containing cyclo-peptides .................................. 67 2.6.5 Solid Phase Synthesis of lactam bridge-containing cyclopeptide ........ 69 2.7 Biological study .................................................................................... 70 2.8 Conformational study. .......................................................................... 72 2.9 NMR analysis ....................................................................................... 73 2.10 NMR Structure Calculations ................................................................. 75 2.11 Conclusion ............................................................................................ 78 3 PART B: Impact of Endocrine disruptor Chemicals on human health ................ 84 3.1 Phthalates .............................................................................................. 85 3.1.1 Metabolism of DEHP in humans .......................................................... 87 3.2 Health effect .......................................................................................... 90 3.2.1 Endocrine disruptor (EDs) .................................................................... 90 3.2.2 PPAR-mediated activity of phthalates .................................................. 91 3.2.3 Alteration of Thyroid Hormone Levels ................................................ 93 3.2.4 Exposure to DEHP in fetuses and infants ............................................. 94 3.3 Detection of DEHP metabolites in urine .............................................. 95 3.4 Synthesis of DEHP metabolites ............................................................ 96 3.5 Quantitative analysis ............................................................................. 97 3.6 Relationships between urinary concentrations of DEHP metabolites, obesity and insulin sensitivity in obese children ................................ 101 3.6.1 Obesity ................................................................................................ 101 3.6.2 Causes ................................................................................................. 102 3.6.3 Mechanism of action ........................................................................... 103 3.7 Detection of DEHP metabolites in obese children ............................. 104 3.8 Results ................................................................................................. 106 3.9 Association between urinary excretion of di(2-ethylhexyl)phthalate secondary metabolites and Autism Spectrum Disorders in children .. 109 ii Chiara Testa, PhD Thesis 3.9.1 Autism Spectrum Disorders ................................................................ 109 3.9.2 Etiology of ASDs ................................................................................ 110 3.9.3 Subjects’ population ........................................................................... 111 3.9.4 Statistical analysis ............................................................................... 112 3.9.5 Results ................................................................................................. 112 4 EXPERIMENTAL PART ....................................................................................... 122 4.1 Materials and methods ........................................................................ 122 5 Solid Phase Peptide Synthesis (SPPS). ................................................................... 124 5.1 General procedure for in batch SPPS on a manual synthesizer .......... 124 5.1.1 Conventional and MW-assisted synthesis of PTHrP(1–34)NH2 ........ 125 5.2 Amino Terminal Acetylation. General Procedure .............................. 126 5.3 Deprotection, Cleavage and Purification of Free Peptide. General Procedure ............................................................................................ 126 5.4 General procedure for solid-phase extraction SPE ............................. 127 5.5 MW-assisted Mini-cleavage. General Procedure ............................... 127 5.6 HPLC Analysis of PTHrP(1–34)NH2 ................................................ 128 5.7 UPLC-ESI-MS Analysis of intermediate fragments of PTHrP(1– 34)NH2 ................................................................................................ 128 6 Synthesis of Nα-Fmoc-ω-azido-α-amino acids and Nα-Fmoc-ω-alkynyl-α-amino acids ........................................................................................................................... 129 6.1 Deprotection of Boc-protecting group. General procedure ............... 129 6.2 Fmoc Protection of the Free Amino Acid. General Procedure ........... 129 6.3 Diazotransfert on ω-aminic group of Nα-Boc or Nα-Fmoc-amin acids with triflic anhydride. General procedure ........................................... 129 6.4 Synthesis of imidazole-1-sulfonyl azide hydrochloride as diazotransfer reagent ................................................................................................. 130 6.5 Diazotransfert on ω-aminic group of Nα-Fmoc- amino acids with Imidazole-1-sulfonyl azide hydrochloride. General Procedure .......... 130 6.5.1 6–Azido–2S-[[(9H-fluoren-9-ylmethoxy)carbonyl] amino]hexanoic acid (6-Azido-Fmoc-L-norleucine) (m=4) .......................................... 131 6.5.2 5-Azido-2S-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]
Load more

Recommended publications
  • The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies
    Nanomaterials 2014, 4, 726-740; doi:10.3390/nano4030726 OPEN ACCESS nanomaterials ISSN 2079-4991 www.mdpi.com/journal/nanomaterials Article The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies Galit Fichman 1,†, Tom Guterman 1,†, Lihi Adler-Abramovich 1 and Ehud Gazit 1,2,* 1 Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; E-Mails: [email protected] (G.F.); [email protected] (T.G.); [email protected] (L.A.-A.) 2 Department of Materials Science and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 6997801, Israel † These authors are equal contributors to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +972-3-640-7498; Fax: +972-3-640-7499. Received: 3 June 2014; in revised form: 28 July 2014 / Accepted: 8 August 2014 / Published: 20 August 2014 Abstract: Amyloid deposits are insoluble fibrous protein aggregates, identified in numerous diseases, which self-assemble through molecular recognition. This process is facilitated by short amino acid sequences, identified as minimal modules. Peptides corresponding to these motifs can be used for the formation of amyloid-like fibrillar assemblies in vitro. Such assemblies hold broad appeal in nanobiotechnology due to their ordered structure and to their ability to be functionalized. The catechol functional group, present in the non-coded L-3,4-dihydroxyphenylalanine (DOPA) amino acid, can take part in diverse chemical interactions. Moreover, DOPA-incorporated polymers have demonstrated adhesive properties and redox activity.
    [Show full text]
  • Identification of Neuropeptide Receptors Expressed By
    RESEARCH ARTICLE Identification of Neuropeptide Receptors Expressed by Melanin-Concentrating Hormone Neurons Gregory S. Parks,1,2 Lien Wang,1 Zhiwei Wang,1 and Olivier Civelli1,2,3* 1Department of Pharmacology, University of California Irvine, Irvine, California 92697 2Department of Developmental and Cell Biology, University of California Irvine, Irvine, California 92697 3Department of Pharmaceutical Sciences, University of California Irvine, Irvine, California 92697 ABSTRACT the MCH system or demonstrated high expression lev- Melanin-concentrating hormone (MCH) is a 19-amino- els in the LH and ZI, were tested to determine whether acid cyclic neuropeptide that acts in rodents via the they are expressed by MCH neurons. Overall, 11 neuro- MCH receptor 1 (MCHR1) to regulate a wide variety of peptide receptors were found to exhibit significant physiological functions. MCH is produced by a distinct colocalization with MCH neurons: nociceptin/orphanin population of neurons located in the lateral hypothala- FQ opioid receptor (NOP), MCHR1, both orexin recep- mus (LH) and zona incerta (ZI), but MCHR1 mRNA is tors (ORX), somatostatin receptors 1 and 2 (SSTR1, widely expressed throughout the brain. The physiologi- SSTR2), kisspeptin recepotor (KissR1), neurotensin cal responses and behaviors regulated by the MCH sys- receptor 1 (NTSR1), neuropeptide S receptor (NPSR), tem have been investigated, but less is known about cholecystokinin receptor A (CCKAR), and the j-opioid how MCH neurons are regulated. The effects of most receptor (KOR). Among these receptors, six have never classical neurotransmitters on MCH neurons have been before been linked to the MCH system. Surprisingly, studied, but those of most neuropeptides are poorly several receptors thought to regulate MCH neurons dis- understood.
    [Show full text]
  • Natriuretic Peptides in Anxiety and Panic Disorder
    CHAPTER FIVE Natriuretic Peptides in Anxiety and Panic Disorder T. Meyer*,†,1, C. Herrmann-Lingen*,† *University of Gottingen€ Medical Centre, Gottingen,€ Germany †German Centre for Cardiovascular Research, University of Gottingen,€ Gottingen,€ Germany 1Corresponding author: e-mail address: [email protected] Contents 1. Neuroendocrine Factors in Anxiety and Fear-Related Disorders 131 2. Molecular Mechanisms Involved in Natriuretic Peptide Synthesis 132 3. Expression of Natriuretic Peptides and Their Receptors in the Brain 135 4. Physiological Actions of Natriuretic Peptides in the Brain 138 5. Neuroprotective Effects of Natriuretic Peptides 139 6. Evidence of Anxiolytic-Like Effects of ANP 140 References 142 Abstract Natriuretic peptides exert pleiotropic effects on the cardiovascular system, including natriuresis, diuresis, vasodilation, and lusitropy, by signaling through membrane-bound guanylyl cyclases. In addition to their use as diagnostic and prognostic markers for heart failure, accumulating behavioral evidence suggests that these hormones also modulate anxiety symptoms and panic attacks. This review summarizes our current knowledge of the role of natriuretic peptides in animal and human anxiety and highlights some novel aspects from recent clinical studies on this topic. 1. NEUROENDOCRINE FACTORS IN ANXIETY AND FEAR-RELATED DISORDERS Anxiety and fear-related disorders, such as generalized anxiety disor- der, panic disorder, agoraphobia, and specific and social phobia, are clinically well-studied conditions characterized by an unpleasant state of inner tension and the expectation of future threat. The nosological entities subsumed under the rubric anxiety and fear-related disorders are usually accompanied by a variety of somatic symptoms, such as sweating, autonomic dysfunction, altered heart rate, abdominal distress, and nausea.
    [Show full text]
  • Vasopressin Generates a Persistent Voltage-Dependent Sodium Current in a Mammalian Motoneuron
    The Journal of Neuroscience, June 1991, 1 f(6): 1609-l 616 Vasopressin Generates a Persistent Voltage-dependent Sodium Current in a Mammalian Motoneuron Mario Raggenbass, Michel Goumaz, Edoardo Sermasi, Eliane Tribollet, and Jean Jacques Dreifuss Department of Physiology, University Medical Center, CH-1211 Geneva, Switzerland During the period of life that precedes weaning, the facial diographical, and biochemical studies have suggestedthat nucleus of the newborn rat is rich in 3H-vasopressin binding vasopressinprobably also plays a role as a neurotransmitteri sites, and exogenous arginine vasopressin (AVP) can excite neuromodulator (Audigierand Barberis, 1985; Buijs, 1987; Du- facial motoneurons by interacting with V, (vasopressor-type) bois-Dauphin andzakarian, 1987;Van Leeuwen, 1987; Freund- receptors. We have investigated the mode of action of this Mercier et al., 1988; Poulin et al., 1988; Tribollet et al., 1988), peptide by carrying out single-electrode voltage-clamp re- and on the basisof behavioral studies, it has been claimed that cordings in coronal brainstem slices from the neonate. Facial this peptide may influence memory storage and retrieval (De motoneurons were identified by antidromic invasion follow- Wied, 1980). Electrophysiological studies have indicated that ing electrical stimulation of the genu of the facial nerve. vasopressincan directly excite selected populations of central When the membrane potential was held at or near its resting neurons (Suzue et al., 1981; Miihlethaler et al., 1982; Ma and level, vasopressin generated an inward current whose mag- Dun, 1985; Peters and Kreulen, 1985; Raggenbasset al., 1987, nitude was concentration related; the lowest peptide con- 1988, 1989; Carette and Poulain, 1989; Liou and Albers, 1989; centration still effective in eliciting this effect was 10 nM.
    [Show full text]
  • Peptoid Morphology Studies and Its Performance in Inhibiting Islet Amyloid Polypeptide Dongwon Park
    University of Arkansas, Fayetteville ScholarWorks@UARK Chemical Engineering Undergraduate Honors Chemical Engineering Theses 5-2016 Peptoid morphology studies and its performance in inhibiting islet amyloid polypeptide Dongwon Park Follow this and additional works at: http://scholarworks.uark.edu/cheguht Recommended Citation Park, Dongwon, "Peptoid morphology studies and its performance in inhibiting islet amyloid polypeptide" (2016). Chemical Engineering Undergraduate Honors Theses. 87. http://scholarworks.uark.edu/cheguht/87 This Thesis is brought to you for free and open access by the Chemical Engineering at ScholarWorks@UARK. It has been accepted for inclusion in Chemical Engineering Undergraduate Honors Theses by an authorized administrator of ScholarWorks@UARK. For more information, please contact [email protected], [email protected]. Peptoid morphology studies and its performance in inhibiting islet amyloid polypeptide Dongwon Park University of Arkansas, Fayetteville May 2016 Table of Contents 1. Introduction 1.1 Misfolded proteins............................................................................................................1 1.1.1 Alzheimer disease (Amyloid beta)..................................................................2 1.1.2 Type 2 diabetes (Amylin) ..............................................................................4 1.2 What is Peptoid ?..............................................................................................................5 2. Previous Research on Misfolded proteins 2.1
    [Show full text]
  • Influence of Cholesterol on Human Calcitonin Channel Formation
    AIMS Biophysics, 6(1): 23–38. DOI: 10.3934/biophy.2019.1.23 Received: 31 October 2018 Accepted: 24 January 2019 Published: 01 February 2019 http://www.aimspress.com/journal/biophysics Research article Influence of cholesterol on human calcitonin channel formation. Possible role of sterol as molecular chaperone Daniela Meleleo* and Cesare Sblano Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari “Aldo Moro”, via E. Orabona 4, 70126 Bari, Italy * Correspondence: Email: [email protected] ; Tel: +390805442775. Abstract: The interplay between lipids and embedded proteins in plasma membrane is complex. Membrane proteins affect the stretching or disorder of lipid chains, transbilayer movement and lateral organization of lipids, thus influencing biological processes such as fusion or fission. Membrane lipids can regulate some protein functions by modulating their structure and organization. Cholesterol is a lipid of cell membranes that has been intensively investigated and found to be associated with some membrane proteins and to play an important role in diseases. Human calcitonin (hCt), an amyloid-forming peptide, is a small peptide hormone. The oligomerization and fibrillation processes of hCt can be modulated by different factors such as pH, solvent, peptide concentration, and chaperones. In this work, we investigated the role of cholesterol in hCt incorporation and channel formation in planar lipid membranes made up of palmitoyl- oleoyl-phosphatidylcholine in which no channel activity had been found. The results obtained in this study indicate that cholesterol promotes hCt incorporation and channel formation in planar lipid membranes, suggesting a possible role of sterol as a lipid target for hCt. Keywords: cholesterol; Human calcitonin; lipid-peptide interaction; planar lipid bilayer; ion channel 1.
    [Show full text]
  • Practice Problems on Amino Acids and Peptides
    AA.1 Practice Problems on Amino Acids and Peptides 1. Which one of the following is a standard amino acid found in proteins? a) CH2 c) Ph e) NH COOH CH2 CH2OH 2 CH 2 CH COOH CH COOH (CH3)2N H2N b) CH3 CH SO3H d) NH2 N COOH 2. Which one of the following amino acids is least likely to be naturally occurring? CO2 O2CNH3 CH2CH2SCH3 CH2SH H3N CO2 H NH3 H NH3 HSH2CH H3N H CH2SH CO2 H CH2CH2SCH3 CO2 AB C D E 3. Amino acids are amphoteric. Which statement best describes the definition of the term amphoteric? A) Amino acids exist as a zwitterion in the solid state B) Amino acids possess both acidic and basic functional groups C) An aqueous solution of an amino acid will conduct electricity D) Amino acids are soluble in water E) Amino acids are colourless AA.2 4. Ninhydrin reacts with most -amino acids to produce a purple compound. Which structure is not reasonably involved in the formation of the compound? O R OH A N CO2 C NH2 O O E O NH2 O O OH R O B N N D N O O O 5. All but one of the natural amino acids react with ninhydrin (I) to give a purple pigment (II). Which one of the five listed will not react with ninhydrin to give II? O O O O N O O O III Asp Cys Met Pro Leu 6. In order to work out the structure of a protein, a necessary first step is to analyze for the amounts of each amino acid contained in it.
    [Show full text]
  • The Action of Morphine Which Increases Gastric
    A COMPARATIVE STUDY ON THE MECHANISM OF ACTION OF MORPHINE ON GASTRIC ACID SECRETION IN DOGS Isamu YAMAGUCHI Research Laboratories, Fujisawa Pharmaceutical Co. Ltd, Yodogaxwa-ku, Osaka, Japan Accepted July 23, 1974 Abstract-While researching the mechanisms of gastric secretagogue action of mor phine, the effects of hexamethonium, atropine and secretin on morphine-induced gastric secretion were studied, and were compared with those on food-, histamine and tetrapeptide-induced gastric secretion in conscious dogs, and on histamine-, tetrapeptide and bethanecol-induced gastric secretion in anesthetized dogs. Effect of acute bilateral vagotomy on the gastric secretion was also investigated in anes thetized dogs. Results are discussed in relation to the mechanisms involved in the stimulation and inhibition of gastric secretion, and the following suggestions are made. Direct vagal excitation of oxyntic glands and endogenous gastrin plays an important role in food-induced secretion in innervated and denervated fundic pouches, respectively. Exogenous gastrin stimulates gastric secretion activating cholinergic post-ganglionic nerve fibers in conscious dogs. In anesthetized dogs, however, exogenous gastrin induces its secretagogue action mainly by a direct action on oxyntic glands. A close similarity was observed between morphine-induced se cretion and food-induced secretion in denervated fundic pouches when inhibitory activities of drugs were compared. It is thus concluded that endogenous gastrin plays an important role in the gastric secretion induced by morphine. The action of morphine which increases gastric secertion was first reported by Riegel (1) as early as in 1900 and it was later shown by Smirnov and Schirokij (2) that this in crease is achieved by way of the vagus nerve.
    [Show full text]
  • Cyclic Natriuretic Peptide Constructs Cyclische Natriuretische Peptidkonstrukte Constructions De Peptides Natriurétiques Cycliques
    (19) TZZ ZZ___T (11) EP 2 001 518 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: (2006.01) of the grant of the patent: A61K 38/10 10.07.2013 Bulletin 2013/28 (86) International application number: PCT/US2007/065645 (21) Application number: 07759833.2 (87) International publication number: (22) Date of filing: 30.03.2007 WO 2007/115175 (11.10.2007 Gazette 2007/41) (54) CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS CYCLISCHE NATRIURETISCHE PEPTIDKONSTRUKTE CONSTRUCTIONS DE PEPTIDES NATRIURÉTIQUES CYCLIQUES (84) Designated Contracting States: (74) Representative: Van Breda, Jacobus et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Octrooibureau Los & Stigter B.V., HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE Weteringschans 96 SI SK TR 1017 XS Amsterdam (NL) Designated Extension States: AL BA HR MK RS (56) References cited: EP-A- 0 223 143 (30) Priority: 30.03.2006 US 743960 P 30.03.2006 US 743961 P • LI BING ET AL: "Minimization of a polypeptide hormone" SCIENCE (WASHINGTON D C), vol. (43) Date of publication of application: 270, no. 5242, 1995, pages 1657-1660, 17.12.2008 Bulletin 2008/51 XP002547160 ISSN: 0036-8075 • DUTTAA.S. JOURNAL OF PEPTIDE SCIENCE vol. (73) Proprietor: Palatin Technologies, Inc. 6, 2000, pages 321 - 341, XP002564522 Cranbury, NJ 08512 (US) • DE VISSER P.C.J.: ’Solid-phase synthesis of polymyxin B1 and analogues via a safety-catch (72) Inventors: approach’PEPTIDE RES. vol. 61, no. 6, June 2003, • SHARAMA, Shubh, D. pages 298 - 306, XP002389978 Cranbury, NJ 08512 (US) • BASTOS, Margarita Remarks: Plainsboro, NJ 08536 (US) Thefile contains technical information submitted after • YANG, Wei the application was filed and not included in this Edison, NJ 08820 (US) specification • CAI, Hui-zhi East Brunswick, NJ 08816 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,434,246 Fukuda Et Al
    US005434246A United States Patent (19) 11 Patent Number: 5,434,246 Fukuda et al. 45 Date of Patent: Jul.18, 1995 Biochemistry, 17(16):3188-3191 (1978). 54 PARATHYROID HORMONEDERIVATIVES F. Cohen et al., The Journal of Biological Chemistry, 75) Inventors: Tsunehiko Fukuda, Kyoto; Shizue Nakagawa; Shigehisa Taketomi, both 266(3):1997-2004 (1991). of Osaka, all of Japan Primary Examiner-Howard E. Schain Assistant Examiner-Phynn Touzeau 73) Assignee: Takeda Chemical Industries, Ltd., Attorney, Agent, or Firm-David G. Conlin; Peter F. Osaka, Japan Corless (21) Appl. No.: 33,099 57 ABSTRACT 22 Filed: Mar. 16, 1993 Parathyroid hormone (PTH) derivatives represented by (30) Foreign Application Priority Data the general formula: Mar. 19, 1992 JP Japan .................................. 4-063517 Ser-Val-R1-Glu-Ile-Gln-Leu-Met-His-Asn-Leu Feb. 18, 1993 JP Japan .................................. 5-029283 Gly-Lys-R2-Met-Glu-Arg-Val-Glu-Trp-Leu-R3 51) Int. Cl......................... C07K 14/00; C07K 4/00; Leu-Gln-Asp-Val-His-Asn-R4 A61K 38/23 52 U.S. Cl. .................................................... 530/324 or a salt thereof, wherein R1 represents Ser or a D-a- 58) Field of Search ............... 530/324;930/DIG. 10; amino acid residue of 4 or less carbon atoms; 514/12 R2 represents a tetrapeptide chain which contains at 56) References Cited least one water-soluble a-amino acid residue; U.S. PATENT DOCUMENTS R3 represents a tripeptide chain which contains at least one water-soluble d-amino acid residue; and 4,086, 196 4/1978 Tregear ............................... 530/324 4,086,198 4/1978 Tregear ............................... 530/324 R4 represents an aromatic amino acid residue or an 4,656,250 4/1987 Morita et al.
    [Show full text]
  • 18.4 Peptides 559
    18.4 Peptides 559 18.4Peptides AIMS: Tonome ond describethe bond thot linksomino ocids together.To drow completestructirol formulos for simple peptides.To controstthe biologicol functionsof some peptide hormones. A peptide is any combination of amino acids in which the alpha amino Focus group (-NH) of one acid is united with the alpha carboxylic group Amino acids are linked to form (-CO2H) of another through an amide bond. peptides. RO RO til ril H2N-C-C-OH + H-N-C-C-OH ------- I H HH Amino acid Amino acid RO RO til ttl H2N-C-C-N-C-C-OH + H2O ttt H HH Peptide The amide bonds formed in peptides always involve the alpha amino and alpha carboxylic acid groups and never those of side chains. More amino acids maybe added in the same fashion to form chains such as those in Figure l9.l. The amide bond between the carbonyl group of one amino acid and the nitrogen of the next amino acid in the peptide chain is called a peptide bond, or peptide link. Amino acids that haue been incorporated into peptides are called amino acid residues. As more amino acid residues are added, a backbone common to all peptide molecules is formed. The amino acid residue with a free amino group at one end of the chain is the N-termi- nal residue:the residue with a free carboxvlic acid at the other end of the chain is the C-terminal residue.The number of amino acid residuesin a peptide is often indicated by a set of preflxes for peptides of up to l0 C-terminal residue Figutel8.l Partsof a peptide-in this case,a tetrapeptide.The peptide bonds of the zigzagbackbone are shown in color.Note that the C-terminalis at the right and the N-terminqlis at the left.
    [Show full text]
  • Chronic Therapy with Elamipretide (MTP-131)
    Original Article Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure Hani N. Sabbah, PhD; Ramesh C. Gupta, PhD; Smita Kohli, MD; Mengjun Wang, MD; Souheila Hachem, BS; Kefei Zhang, MD Background—Elamipretide (MTP-131), a novel mitochondria-targeting peptide, was shown to reduce infarct size in animals with myocardial infarction and improve renal function in pigs with acute and chronic kidney injury. This study examined the effects of chronic therapy with elamipretide on left ventricular (LV) and mitochondrial function in dogs with heart failure (HF). Methods and Results—Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7). LV ejection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-α, and C-reactive protein were measured before (pretreatment) and 3 months after initiating therapy (post-treatment). Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment. In HF-CON dogs, ejection fraction decreased at post-treatment compared with pretreatment (29±1% versus 31±2%), whereas in HF+ELA dogs, ejection fraction significantly increased at post- treatment compared with pretreatment (36±2% versus 30±2%; P<0.05). In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88±120 pg/mL during follow-up but decreased significantly by 774±85 pg/mL in HF+ELA dogs (P<0.001).
    [Show full text]